-

08:07:54 AM

Latest SVA Stock Market News

SVA - Sinovac Biotech, Ltd.

09/09/21 6:00 AM

Nasdaq : SVA

covid-19

New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, Including the Delta Variant

SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced a paper, titled“ A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2,” is available on medRxiv. The findings suggest a third dose of CoronaVac ® can induce a better neutralization breadth to...

RHEA-AI

neutral

09/08/21 4:05 PM

Nasdaq : SVA

covid-19

SINOVAC Announces COVID-19 Vaccine Approved for Emergency Use in Chile for Children and Adolescents

SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that CoronaVac ®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd., a subsidiary of the Company, received approval from the Public Health Institute of Chile for emergency use for children and adolescents aged between...

RHEA-AI

neutral

08/10/21 7:00 AM

Nasdaq : SVA

SINOVAC Announces Positive Data on Booster Shots of CoronaVac®, Induces Strong Immune Response in Adult and Elderly Populations

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today the publication of two papers, which are available on Medrxiv. The publications detail findings from clinical studies on the immunogenicity, safety, and immune

RHEA-AI

negative

07/19/21 7:00 AM

Nasdaq : SVA

SINOVAC Receives Approval on Sabin Strain Based Inactivated Polio Vaccine (sIPV) to Support Global Polio Endgame Strategy

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it received a drug registration approval from the National Medical Product Administration of China (“NMPA”) for its Sabin strain based inactivated polio

RHEA-AI

neutral

07/12/21 5:40 AM

Nasdaq : SVA

SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX

SINOVAC Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with Gavi, the Vaccine Alliance (Gavi), which is on behalf of COVAX Facility, to provide up to 380

RHEA-AI

neutral

06/30/21 6:30 AM

Nasdaq : SVA

clinical trialcovid-19

The Lancet Infectious Diseases Published Data from Sinovac’s Phase I/II Study, World’s First Published Study on Clinical Trial Results of a COVID-19 Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years Old

Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced The Lancet Infectious Diseases published results from the Phase I/II clinical trials of an inactivated COVID-19 vaccine developed by SINOVAC, also known as

RHEA-AI

neutral

06/02/21 7:30 AM

Nasdaq : SVA

World Health Organization Authorizes SINOVAC’s CoronaVac® for Emergency Use

SINOVAC Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that CoronaVac®, an innovative, inactivated coronavirus vaccine developed by SINOVAC Life Sciences Co., Ltd. (“SINOVAC”), a subsidiary of the Company, was

RHEA-AI

neutral

04/22/21 6:51 PM

Nasdaq : SVA

earnings

Sinovac Reports Unaudited Fourth Quarter 2020 Financial Results and Files 2020 Annual Report on Form 20-F

Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2020 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2020. The Company also reported its unaudited

RHEA-AI

neutral

04/01/21 11:30 PM

Nasdaq : SVA

covid-19

Sinovac Announced Buildup of Two Billion Annual Capacity of Its COVID-19 Vaccine

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac®, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line,

RHEA-AI

neutral

02/22/21 4:05 PM

Nasdaq : SVA

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from February 22, 2021 to February

RHEA-AI

neutral

SVA Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.sinovacbio.com
CeoWeidong Yin
Security nameSinovac Biotech, Ltd.
Issue typecs
SectorManufacturing
Sic code2834
Employees1959
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressNo. 15 Zhi Tong Road,
Address2Zhongguancun Tech Park, Changping Distr.
StateBeijing
CityBeijing
Zip102200
CountryChina (Mainland)
Phone861082890088

SVA Description:

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide ('PPV'), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China.